Oncomatrix, National Jewish Health and Case Western Reserve University Join Forces to Attack Invasive Tumors.

The article provides information on license received from National Jewish Health by the Oncomatrix Inc. for use of the human protein Cystatin-C to treat cancer. It informs that the Cystatin-C developed by the Oncomatrix will be used to develop biological drugs for the treatment of pancreas and invasive breast tumors in collaboration with the scientists from Case Western Reserve University and other research centers in the U.S. and Europe.